Home / PDA Letters (Cards)

PDA Letters (Cards)

Implementation Proves Parametric Release Possible

James Assini, Sanofi

Viruses on the Surface

Jennifer Loughman and Paul Lopolito, STERIS

Industry Eyes Future of Visual Inspection

John Shabushnig, PhD, Insight Pharma Consulting; Markus Lankers, PhD, MIBIC; John Ayres, MD, Pharma Safety Solutions; Roy Cherris, Bridge Associates; Robert Miller, Pfizer; Romain Veillon, GSK Vaccines; and Rick Watson, Merck

Big Data is Here to Stay

Aaron Goerke, PhD, F. Hoffmann-La Roche AG, and Michele D’Alessandro, Merck & Company, Inc.

Student Chapter Gains Stem Cell Insights

Kathryn MacDonald, Middlesex Community College

Vaccines, Biosimilars Share Commonalities

Peter Makowenskyj, G-CON Manufacturing

Can the Power of Viruses be Harnessed for Good?

Brian Hawkins, PhD, Pluristyx, Inc.

Change is in the Air for Packaging Components

Rebecca Stauffer, PDA

Biopharma Offers New Opportunities

Cristiana Campa, GSK, and Michael De Felippis, Eli Lilly and Company

A Roadmap to a Continuous Control Strategy

Per Vase, PhD, NNE

PUPSIT & the Proposed Annex 1 Revision

Hal Baseman, ValSource

Expand Your Network and Have Fun!

Rebecca Stauffer, PDA

Thanks for the Warning Letter: Part II

Steven Lynn, Lynn Consulting

Response to "Standing Guard"

Kevin L. Williams, bioMérieux

Global Regulators Partner for Greater Patient Access

Ursula Busse, PhD, Novartis

Take Cell and Gene Therapy Supply Challenges by the Horn

Michael Blackton, Adaptimmune

Are You Up to Speed with Pharma’s Evolving Landscape?

Magaly E. Aham, Takeda Pharmaceuticals

Growth Promotion Testing For EM

Brendan Tindall, biomerieux, and Graham Vesey, Regeneus

Data Integrity Validated as Key Issue

Bruce Loxley, GSK Vaccines, PDA Singapore Chapter Member-at-Large

Alternative to LAL Gains Ground

Stephenie Overman